59-97-2
Chemical Structure
Tolazoline hydrochloride
Synonym(s): Imidaline hydrochloride; NSC35110 hydrochloride
- CAS No.: 59-97-2
- Formula:C10H13ClN2
- Molecular Weight:196.68
IUPAC Name: 2-benzyl-4,5-dihydro-1H-imidazole hydrochloride
InChIKey: RHTNTTODYGNRSP-UHFFFAOYSA-N
SMILES: [H]Cl.C1(CC2=CC=CC=C2)=NCCN1
Biological Activity: Tolazoline hydrochloride (Imidaline hydrochloride) is an α-adrenergic receptor antagonist. Tolazoline hydrochloride inhibits Noradrenaline (HY-13715)-induced cell contraction, modulates vascular resistance, increases arterial pressure, and reverses bradycardia and tachypnea. Tolazoline hydrochloride can be used to study erectile dysfunction, α2-adrenergic receptor agonist-related poisoning, and skin vascular disease research[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tolazoline hydrochloride | 99.93% | Tolazoline hydrochloride (Imidaline hydrochloride) is an α-adrenergic receptor antagonist. Tolazoline hydrochloride inhibits Noradrenaline (HY-13715)-induced cell contraction, modulates vascular resistance, increases arterial pressure, and reverses bradycardia and tachypnea. Tolazoline hydrochloride can be used to study erectile dysfunction, α2-adrenergic receptor agonist-related poisoning, and skin vascular disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tolazoline hydrochloride (Standard) | ≥98% | Tolazoline (hydrochloride) (Standard) is the analytical standard of Tolazoline hydrochloride (HY-A0066A). This product is intended for research and analytical applications. Tolazoline hydrochloride (Imidaline hydrochloride) is an α-adrenergic receptor antagonist. Tolazoline hydrochloride inhibits Noradrenaline (HY-13715)-induced cell contraction, modulates vascular resistance, increases arterial pressure, and reverses bradycardia and tachypnea. Tolazoline hydrochloride can be used to study erectile dysfunction, α2-adrenergic receptor agonist-related poisoning, and skin vascular disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Megens AA, et al. Further validation of in vivo and in vitro pharmacological procedures for assessing the alpha 2/alpha 1-selectivity of test compounds: (1). Alpha-adrenoceptor antagonists. Eur J Pharmacol. 1986 Sep 23;129(1-2):49-55. [Content Brief]
- [2]. Schwartz DD, et al. Selectivity of atipamezole, yohimbine and tolazoline for alpha-2 adrenergic receptor subtypes: implications for clinical reversal of alpha-2 adrenergic receptor mediated sedation in sheep. J Vet Pharmacol Ther. 1998 Oct;21(5):342-7. [Content Brief]
- [3]. Costa P, et al. Adrenergic receptors on smooth muscle cells isolated from human penile corpus cavernosum. J Urol. 1993 Sep;150(3):859-63. [Content Brief]
- [4]. Rogers RA, et al. Pharmacologic modulation of the cutaneous vasculature in the isolated perfused porcine skin flap. J Pharm Sci. 1994 Dec;83(12):1682-9. [Content Brief]
- [5]. Lei L, et al. Activation of L-type calcium channel by tolazoline derivatives: role of isothiocyanate moiety. J Cardiovasc Pharmacol. 1998 May;31(5):721-33. [Content Brief]
- [6]. BENFEY BG, et al. VASOCONSTRICTOR ACTION OF TOLAZOLINE. Br J Pharmacol Chemother. 1964 Feb;22(1):66-71. [Content Brief]
- [7]. Hsu WH, et al. Effects of tolazoline and yohimbine on xylazine-induced central nervous system depression, bradycardia, and tachypnea in sheep. J Am Vet Med Assoc. 1987 Feb 15;190(4):423-6. [Content Brief]
